Your browser doesn't support javascript.
loading
Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer's Disease.
Cope, Zackary A; Murai, Takeshi; Sukoff Rizzo, Stacey J.
Afiliação
  • Cope ZA; Aging Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
  • Murai T; Aging Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
  • Sukoff Rizzo SJ; Aging Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Front Aging Neurosci ; 14: 805063, 2022.
Article em En | MEDLINE | ID: mdl-35250541
ABSTRACT
Continually emerging data indicate that sub-clinical, non-convulsive epileptiform activity is not only prevalent in Alzheimer's disease (AD) but is detectable early in the course of the disease and predicts cognitive decline in both humans and animal models. Epileptiform activity and other electroencephalographic (EEG) measures may hold powerful, untapped potential to improve the translational validity of AD-related biomarkers in model animals ranging from mice, to rats, and non-human primates. In this review, we will focus on studies of epileptiform activity, EEG slowing, and theta-gamma coupling in preclinical models, with particular focus on its role in cognitive decline and relevance to AD. Here, each biomarker is described in the context of the contemporary literature and recent findings in AD relevant animal models are discussed.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article